drugset / Trial / NCT03854578

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

NCT03854578

Phase 1 Completed 73 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated patients with depression.

Timeline

Start
2019-03-12
Primary completion
2019-08-27
Completion
2019-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule 100 mg Oral
Subject Citalopram Small molecule 20 mg Oral